



Symbio Pharmaceuticals Limited
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiosis.co.jp/>

May 21, 2008

Symbio Pharmaceuticals Limited.

Fuminori Yoshida

President and CEO

Symbio Completes Enrollment of Japanese Patients with Indolent non-Hodgkin's Lymphoma in Bendamustine Phase II Clinical Study

TOKYO, May 21, 2008 - Symbio Pharmaceuticals announces the completion of its target enrollment of patients with indolent non-Hodgkin's lymphoma (iNHL) at 18 sites in Japan for the Phase II clinical study of bendamustine HCL, which commenced in December, 2007. Although the completion of enrollment was expected to take 15 months, enrollment was completed ahead of schedule within only 5 months after the study began. The enrollment of study patients with mantle cell lymphoma is also progressing at a good pace, with the target number of patients expected to be realized in the near term. Due to this rapid pace of enrollment, Symbio has shortened its projected timeline for NDA filing which is now expected to be in the 4th quarter, 2009.

Symbio has acquired exclusive rights for the development and commercialization of bendamustine HCL in Japan, China (Hong Kong), Taiwan, Korea and Singapore from Astellas Pharma GmbH (currently, Astellas Deutschland GmbH, München, Germany). In Germany, bendamustine HCL is used as an anticancer drug under the brand name "Ribomustin." On March 20, 2008, Cephalon, Inc. (Frazer, PA) received NDA approval from US FDA for TREANDA[®] (bendamustine hydrochloride) in the treatment of patients with chronic lymphocytic leukemia (CLL). Cephalon, Inc. has filed a supplemental NDA with FDA for use in patients with iNHL who have progressed during or following treatment with rituximab or a rituximab-containing regimen, and expects to receive FDA approval by the 4th quarter of this year. Bendamustine HCL has also been filed MAAs with EMEA for use in the treatment of iNHL, CLL and multiple myeloma (MM) in 13 European countries, excluding Germany and Bulgaria.

[Company Profile]

SymBio Pharmaceuticals Ltd. was established in March 2005 by Fuminori Yoshida, who previously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan, with the corporate mission of addressing underserved therapeutic areas having high medical need in Japan, Korea, Taiwan and other Asia Pacific Rim countries. SymBio's main focus lies in the development of drugs within three therapeutic areas: oncology, hematology and autoimmune disease. Through its proprietary in-house search and evaluation process and experienced management team with strong development expertise in biopharmaceuticals, SymBio is able to implement unique strategies in the development of drug candidates, thereby bringing much-needed therapies to market in an expeditious manner.

For further information, please contact:

SymBio Pharmaceuticals Limited.

Osamu Ogawa,

Board Director, Senior Corporate Officer,

Senior Director, Research & Development

Tel: +081(0)3 5472 1127

E-mail: Please send your inquiry through "INQUIRY" in our homepage

URL:<http://www.symbiosis.co.jp>